Education
About Us
Working with TipRanks
Follow Us
Harrow Health (HROW)
:HROW
HROW Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.86 - $59.23
Previous CloseN/A
Volume51.77K
Average Volume (3M)673.97K
Market Cap
$869.96M
Enterprise Value$1.38B
Total Cash (Recent Filing)$951.88K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.64
Next Earnings
May 19, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding35,654,170
10 Day Avg. Volume656,286
30 Day Avg. Volume673,971
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.98
Price to Cash Flow (P/CF)85.70
P/FCF Ratio107.50
Enterprise Value/Market Cap1.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda69.12
Forecast
1Y Price Target
$59.00Price Target Upside144.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Marketing StrategyThe company's Retina Pivot marketing strategy has been successful, and IHEEZO customer unit demand volume increased 43% sequentially.
Revenue GrowthManagement expects 2025 revenue to be over $280M, which would represent a growth rate over 40%.
Bears Say
Financial ConcernsA delayed 10-K filing is often a cause for concern; in this case, we take management’s reasoning at face value as the incoming auditor requires additional time.
Regulatory RisksRisks include lower-than-projected market uptake of products, inability to develop and secure regulatory approval of pipeline products, inability to acquire new products, inability to service $216M outstanding debt, and potential dilution risk.
---
Ownership Overview
12.15% Insiders
10.36% Mutual Funds
27.90% Other Institutional Investors
38.78% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HROW FAQ
What was Harrow Health’s price range in the past 12 months?
Harrow Health lowest stock price was $9.86 and its highest was $59.23 in the past 12 months.
What is Harrow Health’s market cap?
Harrow Health’s market cap is $869.96M.
When is Harrow Health’s upcoming earnings report date?
Harrow Health’s upcoming earnings report date is May 19, 2025 which is in 33 days.
How were Harrow Health’s earnings last quarter?
Harrow Health released its earnings results on Mar 27, 2025. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.082 by $0.158.
Is Harrow Health overvalued?
According to Wall Street analysts Harrow Health’s price is currently Undervalued.
Does Harrow Health pay dividends?
Harrow Health does not currently pay dividends.
What is Harrow Health’s EPS estimate?
Harrow Health’s EPS estimate is -0.05.
How many shares outstanding does Harrow Health have?
Harrow Health has 35,654,170 shares outstanding.
What happened to Harrow Health’s price movement after its last earnings report?
Harrow Health reported an EPS of $0.24 in its last earnings report, beating expectations of $0.082. Following the earnings report the stock price went down -5.956%.
Which hedge fund is a major shareholder of Harrow Health?
Currently, no hedge funds are holding shares in HROW
---
Harrow Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.00 (144.91% Upside)
$59.00 (144.91% Upside)
Blogger Sentiment
Bullish
HROW Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 550.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
92.88%
12-Months-Change
Fundamentals
Return on Equity
-24.97%
Trailing 12-Months
Asset Growth
24.77%
Trailing 12-Months
Company Description
Harrow Health
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
---
HROW Company Deck
---
HROW Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and strategic product launches, particularly with VEVYE and the retina pivot strategy. However, inventory issues with VEVYE and seasonal impacts on revenue were noted as challenges.Read More>---
HROW Stock 12 Month Forecast
Average Price Target
$59.00
▲(144.91% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
SIGA Technologies
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Best Analysts Covering HROW
1 Year
1 Year Success Rate
9/16 ratings generated profit
1 Year Average Return
+82.73%
reiterated a buy rating 15 days ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +82.73% per trade.
---